Viatris Inc. is a leading pharmaceutical company based in the United States of America that operates in the generic pharma sector. The company was formed in November 2020 as a result of a merger between Mylan N.V. and Pfizer Inc.'s Upjohn business. With a global presence in more than 165 countries, Viatris is committed to providing high-quality, affordable medicines to patients worldwide.

As a responsible corporate citizen, Viatris is committed to reducing its carbon footprint and contributing to the global effort to decarbonize the economy. The company recognizes that climate change is one of the most pressing challenges facing the world today, and it is taking proactive steps to address this issue.

One of the key ways in which Viatris is working to reduce its carbon footprint is through its corporate energy strategy. The company is committed to increasing the use of renewable energy sources and reducing its reliance on fossil fuels. Viatris has set a target to reduce its greenhouse gas emissions by 25% by 2025, and it is working to achieve this goal through a range of initiatives.

One of the key initiatives that Viatris is pursuing is the use of corporate power purchase agreements (PPAs) for renewable energy. PPAs are long-term contracts between a company and a renewable energy provider, which allow the company to purchase electricity from renewable sources at a fixed price. By using PPAs, Viatris is able to secure a stable and predictable source of renewable energy, which helps to reduce its exposure to volatile fossil fuel prices.

In 2020, Viatris signed a 15-year PPA with a wind farm in Texas, which will provide the company with 50% of its electricity needs in the United States. The wind farm is expected to generate 366 megawatts of electricity, which is equivalent to the energy needs of approximately 125,000 homes. This PPA is expected to reduce Viatris' greenhouse gas emissions by approximately 250,000 metric tons per year, which is equivalent to taking 54,000 cars off the road.

Viatris is also investing in on-site renewable energy generation, such as solar panels and wind turbines, at its facilities around the world. The company has installed solar panels at its manufacturing plant in India, which is expected to generate approximately 1.5 million kilowatt-hours of electricity per year. This will help to reduce the plant's reliance on grid electricity and reduce its greenhouse gas emissions.

In addition to its renewable energy initiatives, Viatris is also taking steps to reduce its overall energy consumption. The company has implemented energy efficiency measures at its facilities, such as upgrading lighting systems and HVAC systems, which have helped to reduce its energy consumption and greenhouse gas emissions.

Viatris is also committed to reducing its carbon footprint in its supply chain. The company is working with its suppliers to encourage them to adopt sustainable practices and reduce their greenhouse gas emissions. Viatris has developed a supplier code of conduct, which sets out its expectations for suppliers in areas such as environmental sustainability, labor practices, and human rights.

Overall, Viatris is a leading pharmaceutical company that is committed to reducing its carbon footprint and contributing to the global effort to decarbonize the economy. Through its corporate energy strategy, the company is increasing its use of renewable energy sources, reducing its reliance on fossil fuels, and working to reduce its greenhouse gas emissions. By taking these proactive steps, Viatris is demonstrating its commitment to sustainability and its role as a responsible corporate citizen.